Risk Assessability and Recorded Organ-Protective Therapy Gaps in Type 2 Diabetes: A Five-Center Cross-Sectional Study

Type 2 diabetes is often thought of as a problem with blood sugar, but for many people, it is a condition that quietly damages the body's most vital organs over time. The heart, the blood vessels, and the kidneys are constantly under stress, and this stress can lead to heart attacks, strokes, and kidney failure. For decades, doctors have known that specific medicines can protect these organs. Some drugs help the kidneys work better and reduce heart failure, while others lower the risk of major heart events. There are also older, well-known medicines that prevent heart attacks in people who already have heart disease or that protect the kidneys when blood pressure is high. The medical world has long agreed that using these medicines is the right thing to do. However, knowing the right treatment and actually giving it to the patient are two very different things. In the busy reality of everyday clinics, the path from recognizing a risk to prescribing the right protection is often broken.

A team of researchers set out to map exactly where these breaks happen. They looked at the medical records of more than 32,000 adults with type 2 diabetes across five different hospitals in China. Instead of just counting how many people took a specific pill, the researchers followed a logical path for each patient. First, they checked if the doctors had actually measured the risk. Did they test the urine for signs of kidney damage? Did they check the blood for markers of heart disease? If the risk was not measured, it could not be treated. If the risk was measured and found to be high, the researchers then checked if the patient was eligible for the protective medicine. Finally, they looked to see if that medicine was actually recorded in the patient's file. This step-by-step approach allowed them to see if the problem was a lack of testing, a failure to identify the risk, or a failure to prescribe the treatment.

The study revealed that the journey from risk to protection is frequently interrupted by missing information. In nearly 40 percent of the cases where they looked for signs of kidney damage combined with high blood pressure, the medical records simply did not contain the necessary test results. Without these numbers, a doctor cannot know if a patient needs a specific kidney-protecting drug, even if the patient has the condition. This gap in information was the first major hurdle. Even when the risk was clearly identified and the patient was eligible for treatment, the researchers found that the records often showed no sign that the protective medicine was being used.

The size of these gaps varied depending on the type of protection needed. For patients with signs of kidney disease who should be taking a modern class of drugs known as SGLT2 inhibitors, the records showed a missing treatment in 58.2 percent of cases. For those with a history of heart disease or stroke who should be taking either a modern kidney-heart drug or a GLP-1 receptor agonist, the gap was even larger, affecting 61.4 percent of eligible patients. The situation was slightly better for older, established treatments but still concerning. Among patients with heart disease who should be taking a statin to lower cholesterol, 36.8 percent had no record of receiving one. Similarly, nearly half of the patients with kidney issues and high blood pressure who should be on a specific blood pressure medication were missing that record.

The researchers also looked at whether things were getting better over time. They compared records from the earlier part of their study period with those from the later years. They found that the gap for kidney-protecting drugs narrowed significantly, suggesting that doctors were starting to use these newer medicines more often. However, the picture was not a simple story of overall improvement. The gap for statins actually grew wider in the later years, and the gap for blood pressure medications also increased slightly. This suggests that while progress is being made in some areas, other vital treatments are being overlooked more often as time goes on. The pattern was not the same at every hospital; some centers performed much better than others, indicating that local habits and systems play a huge role in whether a patient receives care.

One of the most important takeaways from this work is a warning about how we interpret medical records. The study emphasizes that a missing record does not necessarily mean a patient did not receive the medicine. A patient might have a prescription from a different doctor, or the medication might have been given but not written down in the specific system the researchers used. The missing record is a signal that something is wrong with the documentation or the process, not a final proof that the treatment was ignored. The researchers argue that the solution is not just to prescribe more drugs, but to fix the workflow. Clinics need to ensure that the necessary tests are done so risks are visible, and then they need to actively check if the right medicines are on the patient's list. By treating organ protection as a measurable process rather than just a guideline, doctors can close the gap between what is known to work and what actually happens in the clinic.